Media Pack
News

Current Edition

JCS Volume 15 Issue 3
 
Europe

MediciNova Announces Full Enrollment in ALS Biomarker Clinical Trial

MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number:4875), t...
31 July 2018 Europe | North America ALS | announces
Continue Reading →
Europe

Bavarian Nordic Announces Initiation of Phase 2 Trial Evaluating the Combination Therapy of CV301 and Nivolumab in Metastatic Colorectal Cancer

Investigator-led study has commenced dosing Immunotherapy candidate CV301 is being assessed in combination with checkpoint inhibitors in multiple solid tumors B...
11 July 2018 Europe announces | Bavarian
Continue Reading →
Europe

NANOBIOTIX ANNOUNCES POSITIVE PHASE II/III TOPLINE DATA IN SOFT TISSUE SARCOMA WITH NBTXR3

Trial achieved its primary endpoint of pathological Complete Response Rate Trial achieved its secondary endpoint in operability (R0 rate) NBTXR3 demonstrat...
27 June 2018 Europe announces | data
Continue Reading →
Europe

Prothena Announces Phase 1b Clinical Trial Results of PRX002/RG7935 for Parkinson’s Disease Published in JAMA Neurology

Prothena Corporation plc (NASDAQ:PRTA), a clinical-stage biotechnology company focused on the discovery and development of novel therapies in the neuroscience categor...
20 June 2018 Europe announces | clinical
Continue Reading →
 

jcs-white.png

Journal for Clinical Studies

Journal For Clinical Studies has a distinguished editorial advisory board providing the best guidelines for global clinical trials. Your resource for Multisite Studies and emerging markets.

Facebook Linkedin
Journal For Clinical Studies © 2023, All Rights Reserved – Powered by Teksyte